Posttransplantation lymphoproliferative disorder involving the central nervous system in liver transplant recipients

Hepatobiliary and Pancreatic Diseases International

Volumn 7, Issue 5, 2008, Pages 551-554

  Xu, Qing Sheng ^a   Ye, Song ^a   Zhou, Yong Qing ^a   Sheng, Jian Feng ^a   Ye, Ke ^a   Zheng, Shu Sen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Central nervous system; Immunosuppression; Liver transplantation; Posttransplant lymphoproliferative disorder

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; CYCLOSPORIN; MYCOPHENOLIC ACID; PREDNISONE;

ADULT; ARTICLE; BRAIN METASTASIS; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DRUG DOSE REDUCTION; GRAFT RECIPIENT; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; LYMPHOPROLIFERATIVE DISEASE; MALE; NEUROLOGIC EXAMINATION; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSTOPERATIVE COMPLICATION; POSTTRANPLANTATION LYMPHOPROLIFERATIVE DISEASE; RECURRENT DISEASE; TREATMENT RESPONSE; VOMITING;

ANTIVIRAL AGENTS; BIOPSY; CARCINOMA, HEPATOCELLULAR; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HEADACHE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 55049103615     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994;97:14-24.
2. Basgoz N, Preiksaitis JK. Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am 1995;9:901-923.
3. Murray JE, Wilson RE, Tilney NL, Merrill JP, Cooper WC, Birtch AG, et al. Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968;168:416-435.
4. Donnelly LF, Frush DP, Marshall KW, White KS. Lymphoproliferative disorders: CT findings in immunocompromised children. AJR Am J Roentgenol 1998;171:725-731.
5. Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995;14:214-221.
6. Buell JF, Gross TG, Hanaway MJ, Trofe J, Roy-Chaudhury P, First MR, et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc 2005;37:954-955.
7. Craig FE, Gulley ML, Banks PM. Posttransplantation lymphoproliferative disorders. Am J Clin Pathol 1993;99: 265-276.
8. Benkerrou M, Durandy A, Fischer A. Therapy for transplant-related lymphoproliferative diseases. Hematol Oncol Clin North Am 1993;7:467-475.
9. Zangwill SD, Hsu DT, Kichuk MR, Garvin JH, Stolar CJ, Haddad J Jr, et al. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant 1998;17:1161-1166.
10. Yu SF, Wu LH, Zheng SS. Genetic factors for individual administration of immunosuppressants in organ transplantation. Hepatobiliary Pancreat Dis Int 2006;5:337-344.
11. Preiksaitis JK. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis 2004;39:1016-1023.
12. Verschuuren EA, Stevens SJ, van Imhoff GW, Middeldorp JM, de Boer C, Koeter G, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002; 73:100-104.
13. Ganne V, Siddiqi N, Kamaplath B, Chang CC, Cohen EP, Bresnahan BA, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 2003;17: 417-422.